A system for small-molecule control of conditionally replication-competent adenoviral vectors

被引:43
作者
Chong, H
Ruchatz, A
Clackson, T
Rivera, VM
Vile, RG
机构
[1] Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA
[2] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
gene transfer; inducible; adenovirus; vector; replication-competent virus; rapamycin;
D O I
10.1006/mthe.2002.0531
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Replication-competent adenoviral vectors are potentially far more efficient than replication-defective vectors. However, for reasons of safety, there is a need to restrict viral replication both spatially, by limiting replication to certain cell types, and temporally. To control replication temporally, we have developed a system, based on the small-molecule dimerizer rapamycin, for regulating the replication of adenoviral vectors. In this system, one adenoviral vector, AdC4, expresses transcription factors whose activity is regulated by the non-immunosuppressive rapamycin analog AP21967. A second vector, Ad(Z12-I-E1aE1b19k), contains E1 genes placed downstream of binding sites for the regulated transcription factor. Co-infection of several cell lines by the vector pair leads to dimerizer-dependent E1 expression and an increase in viral replication, as shown by Southern blots and replication assays. Furthermore, expression of a reporter gene from a replication-defective vector, Ad-GM-CSF, can be augmented by up to 18-fold by co-infection with the pair of conditionally replicating vectors in the presence of dimerizer. Similar results are obtained when the vectors are directly injected into subcutaneous HT1080 xenograft tumors in nude mice. We believe that vectors based on this principle will be a useful additional tool to enhance efficiency and safety of gene delivery for anti-cancer therapy.
引用
收藏
页码:195 / 203
页数:9
相关论文
共 39 条
  • [1] Regulatable systems: applications in gene therapy and replicating viruses
    Agha-Mohammadi, S
    Lotze, MT
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (09) : 1177 - 1183
  • [2] Replicative adenoviruses for cancer therapy
    Alemany, R
    Balagué, C
    Curiel, DT
    [J]. NATURE BIOTECHNOLOGY, 2000, 18 (07) : 723 - 727
  • [3] Complementary adenoviral vectors for oncolysis
    Alemany, R
    Lai, SP
    Lou, YC
    Jan, HY
    Fang, XM
    Zhang, WW
    [J]. CANCER GENE THERAPY, 1999, 6 (01) : 21 - 25
  • [4] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
    Bischoff, JR
    Kim, DH
    Williams, A
    Heise, C
    Horn, S
    Muna, M
    Ng, L
    Nye, JA
    SampsonJohannes, A
    Fattaey, A
    McCormick, F
    [J]. SCIENCE, 1996, 274 (5286) : 373 - 376
  • [5] Regulated gene expression systems
    Clackson, T
    [J]. GENE THERAPY, 2000, 7 (02) : 120 - 125
  • [6] A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
    Freytag, SO
    Rogulski, KR
    Paielli, DL
    Gilbert, JD
    Kim, JH
    [J]. HUMAN GENE THERAPY, 1998, 9 (09) : 1323 - 1333
  • [7] A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
    Fueyo, J
    Gomez-Manzano, C
    Alemany, R
    Lee, PSY
    McDonnell, TJ
    Mitlianga, P
    Shi, YX
    Levin, VA
    Yung, WKA
    Kyritsis, AP
    [J]. ONCOGENE, 2000, 19 (01) : 2 - 12
  • [8] Grewe M, 1999, CANCER RES, V59, P3581
  • [9] A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
    Hallenbeck, PL
    Chang, YN
    Hay, C
    Golightly, D
    Stewart, D
    Lin, J
    Phipps, S
    Chiang, YL
    [J]. HUMAN GENE THERAPY, 1999, 10 (10) : 1721 - 1733
  • [10] An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
    Heise, C
    Hermiston, T
    Johnson, L
    Brooks, G
    Sampson-Johannes, A
    Williams, A
    Hawkins, L
    Kirn, D
    [J]. NATURE MEDICINE, 2000, 6 (10) : 1134 - 1139